CD274 and malignant colon neoplasm: Kim et al. [147] reported that PD-L1 mAb–tMBs can improve therapeutic efficacy, increase the therapeutic index, reduce toxicity, and avoid immune responses and fatalities associated with PD-L1 mAb systemic administration in the treatment of colon cancer.